Clinical trials: Metabolism and Elimination
Healthy
A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
This study will look at how a drug (tucatinib) leaves the body and what happens to tucatinib while it is still in the body. Healthy participants will get one dose of tucatinib by mouth.
- Trial name
- NCT03758339
- Testing
- tucatinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cascadian Therapeutics Inc.
Healthy
A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529
This phase I study is to assess the mass balance recovery after a single oral dose of [14C]-AK0529 in healthy male subjects.
- Trial name
- NCT03400995
- Testing
- AK0529
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Healthy
A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects
The objective of this study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of 14C-JNJ-42847922 in healthy subjects after a single oral dose of 40 milligram (mg) 14C-JNJ-42847922 containing maximally…
- Trial name
- NCT03025022
- Testing
- 14C-JNJ-42847922 40 mg
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteer
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of [14C]-NX-5948.
- Trial name
- NCT06691828
- Testing
- NX-5948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Type 2 Diabetes Mellitus
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients
This study is to evaluate safety and efficacy of ASP1941 after 24 week administration to diabetic patients.
- Trial name
- NCT01672762
- Testing
- ipragliflozin
- Where
- 7 sites in Japan
- Volunteers
- 174 people
- Sponsor
- Astellas Pharma Inc
Healthy Volunteer
A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802
This non-randomized, single group, open-label study will investigate the mass balance, routes of elimination, pharmacokinetics, and metabolism of a single oral dose of RO5424802 and the pharmacokinetics of a 14C-labeled tracer in…
- Trial name
- NCT01981005
- Testing
- RO5424802
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease (PD)
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
- Trial name
- NCT02169427
- Testing
- OPC
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Wilson Disease
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain.
- Trial name
- VARCUWIC (NCT06430359)
- Testing
- urine and blood test
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Healthy Volunteer
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects
This study will be an open-label, non-randomized, absorption, metabolism, and excretion study of [14C]-GDC 0941 administered as an oral dose to 6 healthy male subjects following at least a 10-hour fast from food (not including…
- Trial name
- NCT01474668
- Testing
- GDC-0941
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans
A randomized, double-masked and cross-over dietary intervention study in healthy young adult males to evaluate the concentration of F-derived metabolites in plasma and urine after single acute intakes of F-containing drinks on…
- Trial name
- NCT03201822
- Testing
- 100 mg of Cocoa Flavanols/70 kg BW, 200 mg of Cocoa Flavanols/70 kg BW, 400 mg of Cocoa Flavanols/70 kg BW
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Calcium Deficiency, Vitamin D Deficiency
Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants
The purpose of this study is to demonstrate that the intestinal absorption of calcium from a newly developed calcium carbonate-vitamin D3 chewable tablet formulation increases the amount of calcium excreted in urine and decreases…
- Trial name
- Osteopro (NCT01639222)
- Testing
- Calcium 500 mg and Vitamin D3 800 IU, Low calcium meals
- Where
- Germany
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Osteoporosis, Osteopenia
The Effect of Chymosin on the Intestinal Absorption of Calcium
An adequate calcium intake is important for bone turnover and the risk of developing osteoporosis. Yet many studies have documented that supplementation with calcium tablets are often associated with a poor compliance, therefore…
- Trial name
- Chymosin (NCT01370941)
- Testing
- Drug A Chymosin
- Where
- Denmark
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Healthy Volunteers
A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants
The primary purpose of this study is to evaluate the absolute bioavailability of E7386 following a single oral dose of E7386 as a one 40 milligram (mg) immediate release (IR) tablet and concomitant intravenous (IV) microdose of…
- Trial name
- NCT05607537
- Testing
- E7386 Tablet, (14C)E7386 Capsule, (14C)E7386
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eisai Limited
Healthy Subjects
14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man
This is an open-label study to determine the ADME (Absorption, Disposition, Metabolism and Excretion) of 14C labeled SLV337 after a single dose of an oral suspension.
- Trial name
- NCT01176201
- Testing
- SLV337 suspension, SLV337 capsule
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Abbott Products
Wilson Disease
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
This is a prospective study that will determine the optimal timing for 24-hour urinary copper excretion (UCE) measurement after temporary discontinuation of standard therapies in Wilson Disease (WD) patients.
- Trial name
- NCT07301216
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Healthy Male Subjects
Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects
An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of…
- Trial name
- NCT03770039
- Testing
- Oral PF-06700841 containing 14C microtracer, Oral unlabeled PF-06700841, IV 14C-labeled PF-06700841
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants
The purpose of this study is to characterize the absorption, metabolic pathways of lazertinib, and the excretion of the parent lazertinib and its metabolites, after a single oral dose of 14C-lazertinib in healthy adult male…
- Trial name
- NCT04410081
- Testing
- 14C-lazertinib
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
The detrimental effects of aldostrone are not adequately arrested by the use of angiotensin converting enzyme (ACE), angiotensin II receptor blocker (ARB) or a combination of both.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Essential Hypertension
- Trial name
- NCT01667614
- Testing
- spironolacone 25 mg tablets added to losartan
- Where
- Iran
- Volunteers
- 136 people
- Sponsor
- Tehran University of Medical Sciences
Parkinson Disease
Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole
This study in PD patients is designed to assess the affect food has on the absorption, distribution, metabolism and excretion of ropinirole (by dosing some patients in the fasted state and other patients following a high-fat…
- Trial name
- NCT00460148
- Testing
- Ropinirole
- Where
- 2 sites in Germany, South Africa
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline